Mitsubishi Chemical, a Japanese corporation has agreed to sell its pharmaceutical subsidiary, Tanabe Mitsubishi Pharma, to U.S. private equity firm Bain Capital, according to Reuters on Friday.

U.S. private equity firm Bain Capital has bought Mitsubishi Tanabe Pharma in a deal worth 510 billion yen ($3.4 billion), ...

Japan's Mitsubishi Chemical said on Friday it will sell pharmaceutical unit Tanabe Mitsubishi Pharma to U.S. private equity firm Bain Capital in a deal worth 510 billion yen ($3.36 billion) as it ...

Despite revenue declines, Hillenbrand Inc (HI) focuses on strategic divestitures and strong aftermarket performance to drive ...

Guidance to Reflect Transaction; Maintains Outlook for Remaining Businesses BATESVILLE, Ind., Feb. 5, 2025 /PRNewswire/ -- Hillenbrand, Inc. (NYSE: ...

Brentwood, Tenn.-based Surgery Partners received a nonbinding acquisition proposal from Bain Capital Private Equity on Jan. 27, offering to buy all outstanding shares for $25.75 per share in cash.

Hillenbrand Inc. has announced the sale of a 51 percent stake in its Milacron injection molding and extrusion machinery ...

Hillenbrand anticipates Q2 revenue in the range of $685 million to $705 million and adjusted EPS between $0.53 and $0.58. Full-year guidance has been updated to reflect the Milacron transaction, ...

Taking a look at a Graham Partners-backed technology company that is pursuing a continuation vehicle funding after running a ...

According to the terms of the deal, Bain has agreed to acquire a 51 percent stake in Milacron for $287 million.

Highlights,Hillenbrand's Q1 revenue of $707 million decreased 9% year-over-year, in line with expectations.,The company is ...